Werewolf therapeutics inc
HOWL 投資分析
看多重點:
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足,尚無法提供評分
HOWL 近期報酬表現
2.05%
Werewolf therapeutics inc
1.20%
同產業平均
0.11%
S&P500
與 HOWL 同產業的標的表現
股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
---|---|---|---|---|---|---|---|
MLYS | Mineralys therapeutics inc | - | 5 分 | 4 分 | 2 分 | 1 分 | |
BHVN | Biohaven ltd | - | 5 分 | 2 分 | 3 分 | 1 分 | |
ALLO | Allogene therapeutics inc | 2 分 | 5 分 | 2 分 | 1 分 | 1 分 | |
LYEL | Lyell immunopharma inc | - | 5 分 | 4 分 | 3 分 | 1 分 | |
NRIX | Nurix therapeutics inc | 4 分 | 5 分 | 2 分 | 3 分 | 1 分 |
- MLYS Mineralys therapeutics inc價值 -趨勢 5 分波段 4 分籌碼 2 分股利 1 分查看更多
HOWL 公司資訊
Werewolf Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with pembrolizumab in multiple solid tumor types. WTX-330 is in development as a single agent in metastatic solid tumors and non-Hodgkin lymphoma. Its pipeline also includes JZP898 and WTX-712.